The new portable ultrasound device, which is being showcased at the American Society of Echocardiography (ASE) conference, offers enhanced cardiac imaging as well as shared transducer interoperability and workflows with existing EPIQ CVx and Affiniti CVx ultrasound systems.
The combination of increasing echocardiography volume and clinician shortages continue to require portable imaging options that can facilitate high quality and efficient ultrasound use at the patient bedside. With these issues in mind, Philips is slated to debut the Ultrasound Compact 5500CV device at the American Society of Echocardiography (ASE) conference this weekend.
One of the features of the Ultrasound Compact 5500CV device is AutoStrain, which provides two-dimensional strain quantification of the left ventricle through robust visualization and analysis, according to Philips.
The company said another benefit of the Ultrasound Compact 5500CV include three-hour battery life that facilitates longer scan times. Philips noted the Ultrasound Compact 5500CV also has transducer interoperability and shared workflow with other Philips ultrasound systems such as EPIQ CVx and Affiniti CVx.
“A key advantage of a portable system is the ability to bring the diagnostic power of echocardiography to (patients) wherever they are in an efficient manner. The image quality of the 5500CV allows us to use this advantage without compromising the certainty of the diagnosis,” noted David Liang, M.D., Ph.D, a professor at Stanford University and director of the Hoag Marfan Syndrome and Related Conditions Program at the Hoag Hospital in Newport Beach, Calif.
(Editor’s note: For related content, see “Pie Medical Imaging Launches AI-Powered Echocardiography Platform” and “Mindray Launches New Handheld Ultrasound Device.”)
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.